Search
tedizolid; tedizolid phosphate (Sivextro)
Indications:
- acute bacterial skin infections & skin-structure infections, including infections with MRSA & Enterococcus faecalis [1,2] (FDA-approved June 2014)
- activity against linezolid-resistant S aureus [3]
Contraindications:
- patients taking SSRIs were excluded from clinical trials [3]
Dosage:
- 200 mg PO QD (also intravenous [2])
Antimicrobial activity:
- Staphylococcus aureus (MSSA, MRSA)
- Streptococcus
- Streptococcus pyogenes
- Streptococcus agalactiae
- Streptococcus anginosus
- Streptococcus intermedius
- Streptococcus constellatus
- Enterococcus faecalis
Adverse effects:
- nausea, headache, diarrhea
- less risk for thrombocytopenia than with linezolid [3]
Notes:
- a 6 day course of tedizolid phosphate is non inferior to a 10 day course of linezolid [1]
General
oxazolidinone antibiotic
Database Correlations
PUBCHEM correlations
References
- Prokocimer P et al
Tedizolid phosphate vs linezolid for treatment of acute
bacterial skin and skin structure infections: The ESTABLISH-1
randomized trial.
JAMA 2013 Feb 13; 309:559.
PMID: 23403680
- Doron S and Boucher HW.
Antibiotics for skin infections: New study design and a step
toward shorter course therapy.
JAMA 2013 Feb 13; 309:609.
PMID: 23403687
- Young K
FDA Advisers Recommend Approval of Two Antibiotics.
Physician's First Watch, April 2, 2014
David G. Fairchild, MD, MPH, Editor-in-Chief
Massachusetts Medical Society
http://www.jwatch.org
- FDA News Release. June 20, 2014
FDA approves Sivextro to treat skin infections.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm402174.htm
- Medical Knowledge Self Assessment Program (MKSAP) 17,
American College of Physicians, Philadelphia 2015